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Abstract
Decynium-22 (D-22) is an inhibitor of the uptake2 system of monoamine clearance, resulting in increased levels of dopamine
and norepinephrine (and in some cases serotonin) in the nervous system and elsewhere. Uptake2 is mediated by low-affinity,
high-capacity transporters that are inhibited by glucocorticoids, suggesting a mechanism of fast glucocorticoid-monoamine
interaction in the brain and a possible target for antidepressants. D-22 dose-dependently increased anxiety-like behavior in
adult zebrafish exposed to the light/dark test, monotonically increasing scototaxis (dark preference), but affecting risk
assessment with an inverted-U-shaped response. These results suggest that the uptake2 system has a role in defensive behavior
in zebrafish, presenting a novel mechanism by which stress and glucocorticoids could produce fast neurobehavioral
adjustments in vertebrates.
Related Objects: Preprint - https://doi.org/10.1101/2021.01.14.426728; Protocol - https://doi.org/10.17504/protocols.io.srfed3n;
Dataset - https://doi.org/10.5281/zenodo.5121722
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1. Introduction
Clearance of the monoamine neurotransmitters dopamine (DA),
norepinephrine (NE), and serotonin (5-HT) released in the synap-
tic cleft is executed by two distinct mechanisms, uptake1 and
uptake2 [1–5] . Uptake1 is mediated by high-affinity, low-capacity
transporters which include the NE transporter (SLC6A2, NET),
the DA transporter (SLC6A3, DAT), and the serotonin transporter
(SCL6A4, SERT)[6,7] . This SLC6A family has been implicated in
the pathophysiology of mental disorders, including alterations of
anxiety [8–11] , and are the target for major classes of anxiolytic
drugs, including tricyclic antidepressants, selective 5-HT reup-
take inhibitors, and 5-HT-NE reuptake inhibitors [12] . Uptake2
is mediated by low-affinity, high-capacity transporters which
include organic cation transporters (OCT1-3; SLC22A1-3) and
the plasma membrane monoamine transporter (PMAT; SLC29A4)
[4,5,13–15] . Evidence suggests that uptake2 plays significant roles
in the regulation of monoaminergic neurotransmission and main-
tenance of synaptic homeostasis [2,3,7] , with numerous studies
suggesting that uptake2 plays significant roles in various psycho-
logical disorders, such as anxiety and depression [16–23] .
Uptake2 has been described as an “extraneuronal transport
system” [2,3] , due to its low-affinity, high-capacity, “promiscu-
ous” characteristic, and evidence for that includes the perisynap-
tic location of transporters [1] and the fact that the uptake2 in-
hibitor decynium-22 does not necessarily increase basal serotonin
levels, but may instead produce effects in situations in which 5-
HT brain concentrations are high  [24]. Uptake2 is an interesting
system not only because it is best suited for extraneuronal uptake,
but also because it is blocked by glucocorticoids [13,25] . Glucocor-
ticoids have been shown to inhibit OCT3 [26] , and, with low affin-
ity, PMAT [27] . As a result, uptake2 represents an intersection in
the pathophysiology of stress and anxiety, a mechanism by which
circulating glucocorticoids (GCs) can rapidly increase monoamine
levels in the brain [9] . Uptake2 has been shown to participate in
anxiety-like behavior: SLC22A3 knockout mice show decreased
anxiety-like behavior in the open field test and in the elevated plus-
maze [19, but see 28] . Knockdown of SLC22A3 expression in the
brains of mice decreases immobility time in the forced swim test
[17] , a screen for antidepressant-like effects [29] . Finally, while
decynium-22 (D-22), an uptake2 inhibitor [4] , had no behavioral
effect by itself, co-treatment with fluvoxamine produced synergis-
tic effects on 5-HT clearance and immobility in the forced swim-
ming test [23] .
Zebrafish (Danio rerio Hamilton 1822) have been proposed as
model organisms in the study of behavioral functions and its dis-
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orders [30–33] . The advantages of using this species in behavioral
studies stem from its use in developmental biology (i.e., small size,
fast generation times, high reproduction rates) and the availabil-
ity of tools to image and manipulate its nervous system [33] . Ze-
brafish demonstrate a robust endocrine response to acute stres-
sors [34–37] ; importantly, simple acute stressors such as net chas-
ing induce robust behavioral responses which are blocked by 5-HT
reuptake inhibitors [38,39] and DAergic and NErgic drugs [36,37] .
A few behavioral assays for anxiety-like behavior have been
described for adult zebrafish, with the novel tank test (NTT) and
the light/dark test (LDT) being the most widely used at the mo-
ment [40] . In particular, the LDT involves an approach-avoidance
motivational conflict [41] that results in scototaxis (preference for
dark environments vs brightly-lit or white environments) that is
accompanied by risk assessment (brief entries in the white com-
partment), erratic swimming, freezing, and thigmotaxis while in
the white compartment [40–42] . These variables are particularly
sensitive to anxioselective compounds [40,43] , and drug effects
on scototaxis are negatively correlated with drug effects on 5-HT
turnover [43] . The LDT has been used to investigate the role of
specific 5-HTergic mechanisms [44] , but little is known about the
role of uptake2 in behavior in this test.
Currently, it is unknown whether zebrafish possess a func-
tional uptake2 system. Fourteen slc22 genes have been identified
in zebrafish, and OCT3 appears absent [45,46] ; oct1 shows mod-
erate expression in the brain, suggesting a role in neurotrans-
mitter homeostasis [45] , and therefore is likely to be of behav-
ioral relevance. Little information on zebrafish PMAT is available
[47,48] ; Sivasubbu et al. [49] reported a gene that is “Similar to
solute carrier family 29, member 4” (deposited on ZFIN as ZDB-
GENE-070112-1932 and Ensembl as ENSDARG00000059690), but
expression patterns and function has not yet been described.
Nonetheless, the interplay between serotonin, dopamine, and cor-
tisol in behavioral responses to threatening and stressful stimuli in
zebrafish [see 50 for a review] suggests a participation of uptake2.
Here, I show that D-22 dose-dependently increases anxiety-like
behavior in the zebrafish LDT. These results suggest that uptake2
is present in this species, and that it functions as a mediator of
stress and defensive behavior.
This manuscript is a complete report of all the studies per-
formed to test the hypothesis of a dose-dependent effect of D-22
on anxiety-like behavior. I report all data exclusions, all manipu-
lations, and all measures in the study.
2. Materials andmethods
2.1. Animals and housing
A total of 100 animals were used. Animals were bought from a
commercial vendor (AcquaPeixes, Goiânia/GO, Brazil) and arrived
in the laboratory with an approximate age of 3 months (standard
length = 13.2 ± 1.4 mm), and were quarantined for two weeks;
the experiment began when animals had an approximate age of
4 months (standard length = 23.0 ± 3.2 mm). Housing standards
were as described by Pimentel et al. [51]: “Animals were kept
in mixed-sex tanks during acclimation, with an approximate ra-
tio of 50-50 males to females (confirmed by body morphology).
Adult zebrafish from the wildtype strain (longfin phenotype) were
used in the experiments. Outbred populations were used for in-
creased genetic variability, thus decreasing the effects of random
genetic drift which could lead to the development of uniquely her-
itable traits [52,53] . Thus, the animals used in the experiments
were expected to better represent the natural populations in the
wild. The breeder was licensed for aquaculture under Ibama’s
(Instituto Brasileiro do Meio Ambiente e dos Recursos Naturais
Renováveis) Resolution 95/1993. Animals were group-housed in
40 L tanks, with a maximum density of 25 fish per tank, for at
least 2 weeks before experiments begun. Tanks were filled with
non-chlorinated water at room temperature (28 °C) and a pH of
7.0-8.0. Lighting was provided by fluorescent lamps in a cycle
of 14-10 hours (LD), according to standards of care for zebrafish
[54] . Water quality parameters were as follows: pH 7.0-8.0; hard-
ness 100-150 mg/L CaCO3; dissolved oxygen 7.5-8.0 mg/L; ammo-
nia and nitrite < 0.001 ppm. All manipulations minimized their
potential suffering of animals, and followed Brazilian legislation
[55] . Animals were used for only one experiment and in a sin-
gle behavioural test, to reduce interference from apparatus expo-
sure. Experiments were approved by UEPA’s IACUC under protocol
06/18.”
2.2. Sample size calculation and exclusion criteria
Sample sizes were calculated based on a power analysis, using the
effects of fluoxetine on the light/dark test [44] as estimates of ef-
fect sizes. Using an effect size of 0.7, a significance level of 0.005,
and a power of 90%, a sample size of 11 animals per group was cal-
culated. Final sample sizes were 20 animals/group. Animals were
excluded if they displayed signals of overt ataxia (swimming on a
side, swimming upside-down, vertical swimming) during the ex-
posure period [56]. Outliers were detected using an a priori rule
based on median absolute deviation (MAD) of time on white (the
main endpoint of the LDT), with values above or below 3 MADs be-
ing removed [57] .
2.3. Drug treatments
Zebrafish were randomly drawn from the holding tank immedi-
ately before injection and assigned to four independent groups
(n = 20/group). Animals were injected with vehicle (Cortland’s
salt solution) or D-22 (CAS #977-96-8, Cat#: 323764, Sigma-
Aldrich/Merck, Brazil; 0.01, 0.1, 1, or 10 mg/kg). The injection vol-
ume was 1 µL/0.1 g b.w. following procedures described by Kinkel
et al. [58]. The order with which groups were tested was random-
ized via generation of random numbers using the randomization
tool in http://www.randomization.com/. The experimenter and
data analyst was blinded to treatment by using coded vials for drug
doses and by using coding to reflect treatments in the resulting
datasets; after analysis, data was unblinded. Codes were created
and kept by a research assistant.
2.4. Light/dark test
The light/dark preference (scototaxis) test was performed as de-
scribed elsewhere [32, 59]. Animals were individually tested, and
groups were independent from each other. 30 min after drug in-
jection, an individual was individually transferred to the central
compartment of a half-black, half-white tank (15 cm height × 10
cm width × 45 cm length; Figure 1A) and left for 3 min, during
which the animal acclimated to the tank. After this acclimation
period, the doors which delimit this compartment were removed,
allowing the animal to freely explore the apparatus. Spatiotem-
poral variables (below) were recorded for the entire 15 min trial.
While the whole experimental tank was illuminated from above by
a homogeneous light source, due to differences the reflectivity of
the apparatus walls and floor average illumination (measured just
above the water line) above each compartment was different: 225
± 64.2 (mean ± S.D.) lux above the black compartment, and 307
± 96.7 lux above the white compartment. A digital video camera
(Samsung ES68, Carl Zeiss lens) was installed above the appara-
tus to record the behavioral activity of the zebrafish. The following
variables were recorded:



































































































































































































































































































































































































































































Figure 1. (A) Test apparatus. (B) Scototaxis (time spent in the white compartment). (C) Transitions to the white compartment. (D) Duration of entries in the white
compartment. (E) Risk assessment. (F) Erratic swimming. (G) Thigmotaxis. (H) Freezing duration. The Hedges’ g for 4 comparisons against the shared control 0 mg/kg
are shown in the above Cumming estimation plots. The raw data is plotted on the upper axes. On the lower axes, mean differences are plotted as bootstrap sampling
distributions. Each mean difference is depicted as a dot. Each 95% confidence interval is indicated by the ends of the vertical error bars. 5000 bootstrap samples were taken;
the confidence interval is bias-corrected and accelerated. Letters indicate results from post-hoc tests; different letters indicate statistically significant differences (p < 0.05).
of the tank (s);
• White transitions: the number of entries in the white compart-
ment made by the animal throughout the session;
• Entry duration: the average duration of an entry (time on white
/ transitions);
• Numberof erraticmovements: defined as the number of zig-zag,
fast, and unpredictable swimming behavior of short duration;
• Duration in freezing: the duration of freezing events (s), defined
as complete cessation of movements with the exception of eye
and operculum movements;
• Duration in thigmotaxis: the duration of thigmotaxic events (s),
defined as swimming in a distance of 2 cm or less from the
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white compartment’s walls;
• Frequency of risk assessment: defined as a fast (<1 s) entry in the
white compartment followed by re-entry in the black compart-
ment, or as a partial entry in the white compartment (i.e., the
pectoral fin does not cross the midline).
Two independent observers, blinded to treatment, manu-
ally measured the behavioral variables using X-Plo-Rat 2005
(https://github.com/lanec-unifesspa/x-plo-rat). Inter-observer
reliability was at least > 0.95.
2.5. Data analysis
Drug effects were assessed using asymptotic general indepen-
dence tests, using the R package ‘coin’ [60] . Independence tests
are conditional, resampling-based procedures which replace the
unknown null distribution by a conditional null distribution (i.e.,
the distribution of a given test statistic given the actually observed
data), and are therefore not limited by distributional assumptions
and by the assumption that random samples of a population (in-
stead of randomization of a nonrandom sampling) took place [60–
62] . Post-hoc analysis was made using pairwise permutation tests
with correction for the false discovery rate. Data were presented
as Cumming estimation plots, with Hedges’ g used to estimate
effect sizes, using the R package DABESTR [63] . Cumming esti-
mates were made using 5000 bootstrap resamples, and confidence
intervals were bias-corrected and accelerated. Bootstrapping was
used to derive sampling-error curves due to the robustness of
this method in relation to deviances from normality and unequal
variances [64] . Estimation statistics were chosen for graphical
representation because they estimate effect sizes and their un-
certainties, emphasizing quantitative reasoning beyond dichoto-
mous thinking (effect/no effect)  [63,65].
3. Results
5 animals were removed from analysis in the highest dose group
due to overt ataxia, and 2 animals were removed from the 1 mg/kg
group for the same reason. 1 animal from the 1 mg/kg group was
detected as outlier and removed from further analysis. A dose-
dependent decrease in time on white was found (maxT = -3.773,
p = 0.0007; Figure 1B); significant effects were found for 0.1-10
mg/kg. Likewise, dose-dependent decreases were found for tran-
sitions to white (maxT = 4.0277, p = 0.0003; Figure 1C); significant
effects were found for all doses, except 0.1 mg/kg. No significant
effects were found for entry duration (maxT = 1.8191, p = 0.2779;
Figure 1D). An inverted-U-shaped response was found for risk as-
sessment (maxT = 4.6248, p = 0.019; Figure 1E), with 0.1, and 1
mg/kg increasing risk assessment, and 0.01 mg/kg having no ef-
fect; the effect of 10 mg/kg was smaller than the other effects. A
main effect of dose was found in erratic swimming (maxT = 3.106,
p = 0.0091; Figure 1F), but post-hoc comparisons failed to detect
differences. No effects were found for thigmotaxis (maxT = 2.1474,
p = 0.1396; Figure 1G) or freezing (maxT = 2.0629, p = 0.1688; Fig-
ure 1H). Table 1 presents false discovery rate-adjusted p-values for
multiple comparisons.
4. Discussion
The present experiment showed evidence that D-22, an uptake2
inhibitor, dose-dependently increased anxiety-like behavior in
the LDT in unstressed zebrafish. Dose-dependent effects were
found for time on white (scototaxis), transitions to white, and risk
assessment, with the latter suggesting better effects at interme-
diate doses (0.1 and 1 mg/kg). No effects were observed in other
variables (freezing and erratic swimming, thigmotaxis). D-22 de-
creased time on white (suggesting an increase in preference for
dark), an index of anxiogenic-like effects [40,41,43,66] , at doses
of 0.1 mg/kg and higher, while decreasing transitions to white and
increasing risk assessment. In general, effect sizes for time on
white and transitions to white were small, while effect sizes for
risk assessment were average.
The LDT has been proposed as a screening test for anxiolytic-
like and anxiogenic-like effects of treatments in adult zebrafish
[66] . The test shows good predictive validity, being sensitive to
agents that act at different targets [40]. The main endpoint of
this test, light/dark preference, is sensitive to anxiolytic-like and
anxiogenic-like effects, and represents an “avoidance” dimension
of behavior in the LDT, while risk assessment clusters in a differ-
ent group and represents a more “cognitive” aspect of anxiety-
like behavior [43] . Moreover, exposure to the LDT induces a corti-
sol response in unstressed animals [40] , suggesting that the con-
flict that is induced in the test is mildly stressful.
Behavioral effects of D-22 have been described in rodents;
while by itself D-22 (0.01-0.32 mg/kg) was not able to change
immobility time in the tail suspension test in mice, a screen for
antidepressant-like effects, it produced a synergistic effect with
fluvoxamine [23] . Species- and strain-specific effects can be re-
sponsible for this lack of effect of D-22, as this drug (0.001-0.01
mg/kg) reduced immobility time in the forced swim test (an-
other screen for antidepressant-like effects) in Wistar-Kyoto, but
not Long Evans, rats [67] . Although these effects are usually at-
tributed to effects on serotonin clearance [1], it is not possible to
discard an effect on norepineprhine.
Importantly, effects of manipulations of the uptake2 system
in rodents produce either opposite [19] or no effect [28] in trans-
genic mice. These differences could be attributed to a role of
monoamines in adulthood (e.g., fast modulation of mood and be-
havior) vs. their roles during development [68–70] . Similar ef-
fects are observed with acute drug treatment vs. transgenics
in the case of serotonin transporters [e.g. 71] , suggesting that
monoamines participate in the development of brain regions that
are involved in defensive/emotional behavior, and that lacking
monoamine transporters disrupts these developmental trajecto-
ries in ways that acute drug treatment does not. Indeed, it has been
shown that serotonin participates in the development of neural cir-
cuits associated with emotion in a sensitive developmental win-
dow [71] , and since knocking out uptake2 transporters from birth
should affect the levels of monoamines at periods which are critical
for the development of neurocircuits associated with anxiety-like
behavior, the effects of this manipulation are expected to be differ-
ent than acute treatment with D-22 in adult animals.
D-22 blocks the uptake2 monoamine transport system [1] . D-
22 does not readily discriminate between OCT and PMAT sys-
tems [72] , and therefore it is currently impossible to pharma-
cologically uncouple both transporters. Due to its low-affinity,
high-capacity character, transporters in the uptake2 system (OCT
and PMAT) are “promiscuous”, participating in the elimination of
most monoamines from synaptic and extrasynaptic sites [73] . Im-
portantly, uptake2 may represent a link between acute stress and
monoaminergic neurotransmission [9] , as these transporters are
blocked by glucocorticoids [25]. While currently it is not known
whether the effects reported in this experiment are due to sero-
tonin, norepinephrine, dopamine, or histamine, there is some ev-
idence for anxiety-like behavior in zebrafish being increased by
serotonin [74] and catecholamines [37] .
Overall, these results suggest that uptake2 is present in ze-
brafish, and that it functions as a mediator of stress and defensive
behavior. These results point to novel avenues of investigation in
the stress-monoamine interaction in anxiety, stress, and defen-
sive behavior. Further studies are needed to better understand the
mechanisms by which D-22 produces its behavioral effects.
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Table 1. False discovery rate-adjusted p-values for multiple comparisons
Endpoint Dose vs 0.01 mg/kg 0.1 mg/kg 1 mg/kg 10 mg/kg
Time on white 0 mg/kg 0.2648 0.0050 0.0003 0.0056
0.01 mg/kg 0.0048 0.0634 0.0056
0.1 mg/kg 0.0018 0.8041
1 mg/kg 0.0056
Transitions to white 0 mg/kg 0.0053 0.3522 0.0007 0.0035
0.01 mg/kg 0.0324 0.0078 0.3303
0.1 mg/kg 0.0025 0.0137
1 mg/kg 0.0137
Entry duration 0 mg/kg 0.7876 0.8143 0.7888 0.7875
0.01 mg/kg 0.7876 0.7876 0.7876
0.1 mg/kg 0.8143 0.7888
1 mg/kg 0.8143
Risk assessment 0 mg/kg 0.5085 < 0.0001 < 0.0001 0.0159
0.01 mg/kg < 0.0001 < 0.0001 0.0124
0.1 mg/kg 0.2216 0.0865
1 mg/kg 0.0184
Erratic swimming 0 mg/kg 0.9562 0.0594 0.9562 0.0594
0.01 mg/kg 0.0594 0.9243 0.0594
0.1 mg/kg 0.0817 0.3241
1 mg/kg 0.0594
Thigmotaxis 0 mg/kg 0.2386 0.0152 0.8082 0.0385
0.01 mg/kg 0.0449 0.5570 0.0794
0.1 mg/kg 0.0449 0.8553
1 mg/kg 0.0770
Freezing 0 mg/kg 0.2865 0.3952 0.0609 0.2865
0.01 mg/kg 0.9243 0.2865 0.6259
0.1 mg/kg 0.3952 0.7481
1 mg/kg 0.5310
Significance statement
Uptake2 is a low-affinity, high-capacity transport system that
contributes to the clearance of extraneuronal monoamines
(mainly norepinephrine, serotonin, and dopamine) and is
sensitive to glucocorticoids, therefore representing a putative
mechanism of glucocorticoid-monoamine interaction. Since
both monoamines and glucocorticoids have been implicated
as mediators of stress-induced behavioral adjustments, this
interaction can be of relevance to understanding the mechanisms
through which stress influences neurochemical and behavioral
responses. Here I report that, in zebrafish, the uptake2 inhibitor
decynium-22 increases dark preference and risk assessment in
the light/dark test, an assay for anxiety-like behavior. Thus,
uptake2 appears to act as a modulator of defensive behavior,
and its inhibition by, e.g., glucocorticoids could represent a
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For the benefit of readers, reviewers are asked to write a public
summary of their review to highlight the key strengths and weak-
nesses of the paper. Signing of reviews is optional.
Reviewer 1 (Anonymous)
This paper showed that decynium-22 (D-22; an uptake2 inhibitor)
produced a dose-dependent increase in scototaxis and risk taking
behaviour without altering other anxiety-related behaviours such
as thigmotaxis or freezing. This experiment shows for the first
time that zebrafish do indeed have an uptake2 mechanism, but
more research is needed to understand which neurochemicals play
a role in this mechanism (dopamine, serotonin, norepinephrine or
histamine).
Reviewer 2 (Anonymous)
Overall, the paper presents an interesting finding about the inter-
action of D-22 with neuronal receptors in zebrafish. Convincing
evidence is presented that zebrafish have a similar mechanism of
stress-anxiety response mediated by uptake2 receptors compared
to other vertebrates. However, since the mechanism of D-22 is not
detailed and the findings contradict other studies looking at the
uptake2 system, it is unknown the true effect of the drug. The be-
havioral studies were blinded for both researcher and behavioral
evaluator which is a strength of the study. In addition, the authors
use a well established behavioral test as well as strong interpre-
tation measures for the data. Finally, this paper adds important
knowledge of the existence of the uptake2 system in zebrafish as
well as its possible role in defense behaviors.
Reviewer 3 - Statistical Review (Shawn Zheng Kai Tan,
European Bioinformatics Institute (EMBL-EBI), United
Kingdom.)
In their manuscript, the author uses, in my opinion, non-
standard, though rather progressive statistics and visualisations
to measure the effects of various dosages of decynium-22 on be-
havioural measures in zebrafish light/dark test. The data and
statistics in this paper are fully disclosed and available on their
github, something that should be applauded. While the author has
employed admirable statistical methodology that addresses some
issues in the field, the major issue I have is the lack of justifica-
tion/explanation of them. Even if these statistics were more com-
mon in the zebrafish field (which I am not sure they are), the wider
behavioural neuroscience readership of the journal would likely
find it useful to further understand these choices. Therefore, hav-
ing the right papers cited, together with basic explanation of why
the statistical methods were chosen would greatly increase trust in
the statistical methods, and help the reader understand why such
methods were used.
Reviewer 4 - References Review (Anonymous)
I examined the literature review and checked cited references for
appropriateness. I found no evidence of citations to predatory jour-
nals or papers under editorial notices and references generally pro-
vided good support to the claims that they were being cited for.
However, I did find several instances where the introduction of
the uptake1 and uptake2 systems could have provided a more com-
plete and nuanced description of the system. For example, while
papers showing glucocorticoid inhibition of uptake2 were cited,
there are also papers that suggest only low affinity inhibition of
PMAT by corticosterone. I also suggested several citations to fa-
cilitate a more complete description of uptake1/uptake2 and in a
couple of places I suggested alternative citations that provided a
more up-to-date or comprehensive discussion of issues. I am not
an author on any of the citations I recommended.
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